Power of Story
Send a Tweet        
- Advertisement -

Share on Google Plus Share on Twitter Share on Facebook Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend 1 (1 Shares)  

Printer Friendly Page Save As Favorite View Favorites (# of views)   No comments
General News

FDA Needs To Ban Accutane

By       Message Evelyn Pringle     Permalink
      (Page 1 of 4 pages)
Related Topic(s): ; ; ; ; ; ; ; ; ; ; (more...) ; ; ; ; ; ; ; ; ; , Add Tags  (less...) Add to My Group(s)

View Ratings | Rate It

opednews.com

- Advertisement -
Unfortunately hundreds of parents already know that Accutane can cause some teenagers to commit suicide, but new evidence of a link between the acne drug and depression in the journal, Neuropsychopharmacology, will hopefully put an end to the years of claims by Hoffman-LaRoche that its drug is not responsible for the suicides.

Scientists from Bath University, with the University of Texas in Austin, reveal in the journal, Neuropsychopharmacology that experiments conducted on mice show that Accutane makes the rodents behave in ways recognized as depression.

Isotretinoin is a synthetic retinoid used as an oral treatment for severe nodular acne that has been linked with depression and suicide in patients. Isotretinoin is also sold under the brand names of Accutane, Roaccutane, Amnesteem, Claravis and Sotret.

The purpose of the Neuropsychopharmacology study was to test the theory that chronic administration of Accutane could lead to depression related behaviors in mice.

- Advertisement -
In the study, young male mice were given Accutane by daily injection for 6 weeks, which produced blood levels of the drug comparable to those reported in human patients taking Accutane.

"You can't ask a mouse if it is depressed," researcher Sarah Bailey, of the University of Bath, said. "So we used two tests to model behaviour."

Both tests involved putting the mice under stress. In one test, the mice were suspended by their tails and in the other, they were put in water and forced to swim. Under these circumstances, the study author's note, normal mice will swim, climb or thrash around in attempt to escape, in between periods of immobility when they appear to be resigned.

- Advertisement -
But a mouse that is depressed will spend a longer time in the immobile state than a normal mouse. In both the forced swim test and the tail suspension test, the researchers found that Accutane treated mice spent significantly more time immobile compared to mice who were not on the drug.

For years, Roche has denied that Accutane causes depression and suicide and internal FDA documents show the agency was aware of these risks almost since the drug came on the market.

In 1985, Accutane's package insert for physicians first mentioned reports of depression in patients being treated with Accutane. In 1986, the physicians were again notified that Accutane users who became depressed saw their depression go away when they discontinued the use of Accutane but that the depression came back if patients went back on the medication. Doctors were also informed that simply removing the patient from Accutane treatment may not be sufficient to treat the depression and that a follow up for depression may be necessary.

Jumping ahead to a decade later, a 1998 FDA memo states that: "Given all the pieces of evidence available, it is difficult to avoid the conclusion that Accutane can adversely affect the adult human brain in clinically significant ways and that Accutane use is associated with severe psychiatric disease in some patients."

The FDA memo recommends "active consideration of removal of Accutane from the market." The recommendation was ignored.

In April 1998, the FDA instructed Roche to strengthen the warnings on Accutane and alert doctors to the risks of "depression, psychosis and, rarely, suicidal ideation, suicide attempts and suicide."

- Advertisement -
But even then, Roche continued to mislead potential customers about the risks of suicide. Two weeks after the label change, on March 5, 1998, the FDA sent a warning letter to Roche telling the company to cease "false and misleading" advertisements which promote Accutane as an "effective treatment of severe acne... [that] minimizes negative psychosocial effects such as depression and poor self-image."

The FDA stated that, "This claim is particularly troublesome in light of information recently presented in a Dear Doctor letter that Accutane may cause depression, psychosis, and rarely, suicidal ideation, suicide attempts and suicide."

In conclusion, the FDA ordered Roche to "prominently disclose information about the psychiatric disorders described in the warnings section of the revised labeling" in Accutane ads.

Next Page  1  |  2  |  3  |  4

 

- Advertisement -

View Ratings | Rate It

Evelyn Pringle is a columnist for OpEd News and investigative journalist focused on exposing corruption in government and corporate America.

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon



Go To Commenting
The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
- Advertisement -

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Glaxo Promotes Mental Disorders - Then Paxil

Government Investigation Finds Autism Vaccine Related

Paxil Five-Year Litigation History

Suicide Risk of Neurontin Kept Hidden for Years

Gambro Healthcare - Dialysis Fraud Pays Big Bucks

Johnson & Johnson Chirate Spinal Disc Under Fire